New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

CytoMed Therapeutics Limited (GDTC) vs Vyome Holdings, Inc. (HIND)

CytoMed Therapeutics Limited and Vyome Holdings, Inc. are both Biotechnology companies. Vyome Holdings, Inc. is the larger, with a market value of $10.2M against $9.2M — 1.1× the size. Across the 7 metrics below, Vyome Holdings, Inc. leads on 4 and CytoMed Therapeutics Limited on 3.

Valuation

Metric GDTC HIND Biotechnology median
P/E n/m n/m 8.49
P/S — 55.90 8.56
P/B 0.51 1.31 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA n/m n/m 0.69
EV/Sales — 12.73 8.00
Earnings yield (35.90%) (48.42%) (35.81%)
Free cash flow yield (0.43%) (52.40%) (25.41%)

Profitability

Metric GDTC HIND Biotechnology median
Gross margin — 50.39% 70.18%
Operating margin — (2,851.63%) 0.00%
Net margin — (2,453.92%) 0.00%
Free cash flow margin — (2,928.92%) 0.00%
Return on equity — (71.85%) (51.58%)
Return on assets — (48.02%) (45.91%)
Return on invested capital — 0.00% 0.00%

Growth

Metric GDTC HIND Biotechnology median
Revenue growth (TTM) — (55.55%) 7.20%
EPS growth (last fiscal year) (68.75%) 99.92% 29.04%
Revenue growth, 5-year CAGR — (50.98%) 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric GDTC HIND Biotechnology median
Debt to equity 80.30 0.05 0.00
Current ratio 2.64 3.68 4.79
Net debt to EBITDA 0.86 0.48 1.01

Dividend

Metric GDTC HIND Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric GDTC HIND Biotechnology median
Market cap 9.15m 10.18m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack